Concanavalin-A (con-A) is a plant lectin isolated from the jack bean (Concanavalus species). It binds specifically a-D-glucosyl, a-D-mannosyl, and sterically related structures. Polysaccharides containing these residues in the terminal position will cross-react with con-A forming large complexes of low solubility. Binding is specific and of high affinity, and can be measured by any technique applicable to antigenantibody interactions.' The majority of serum acute phase reactant proteins are glycoproteins containing residues which will bind to, and be precipitated by, con-A. It has recently been shown that con-A binding can therefore be used as a means of measuring acute phase proteins in the blood of both man and animals. 2 Serum acute phase proteins are widely used to assess the activity and prognosis of rheumatoid arthritis.3 The sequential changes in serum levels have also been used as a means of assessing treatment responses to second line drugs such as gold and penicillamine.4 C-reactive protein (CRP) Table 1 shows the con-A binding recorded in 100 healthy blood donors compared with that of the 50 patients with rheumatoid arthritis. Con-A binding was significantly higher in patients with rheumatoid arthritis, although the groups were not age or sex matched. The Table also shows the correlations between CRP, con-A, and blood viscosity in rheumatoid arthritis, all of which were statistically significant. are shown in Table 2 . There was a significant improvement in pain score, Ritchie index, and early morning stiffness, indicating an overall satisfactory response to therapy. The changes in laboratory measurements are also shown in Table 2 and Fig. 2 . There was a statistically significant increase in haemoglobin and a fall in blood viscosity. After 6 months there was also a significant fall in IgG and IgM levels and in rheumatoid factor titre, indicating that the change in disease status expected with penicillamine was achieved in this group of patients. There was also a significant fall in both con-A binding and CRP during the duration of the study (Fig. 2) . However, as shown in Table 3 the correlation between con-A, CRP, and blood viscosity altered during the treatment period. In several patients con-A binding and CRP changed in different directions; this is reflected by the decreased correlation coefficient between the 2 measurements after 6 months' penicillamine therapy. The results of the present study showed that con-A binding is significantly higher in patients with rheumatoid arthritis than in normal persons, and there was a significant correlation between CRP and con-A binding in a cross-sectional study. This result was expected in view of the known ability of con-A to react with many of the acute phase reactants. Previous studies have also shown good correlations between con-A binding and other acute phase proteins in inflamnmatory diseases in man, including RA.1212 Sequential studies of a range of acute phase proteins and of con-A binding were carried out to assess variation from week to week in the absence of alterations in treatment. These studies showed a good correlation between all measurements, and in a majority of the patients similar levels were recorded on each of the 6-week estimations, suggesting that con-A binding is providing a simple and reproducible measurement of the serum acute phase response in patients with RA. We are grateful to the Arthritis and Rheumatism Council for financial support and to Mrs M. Clarke for secretarial assistance.
